- Home
- MIRA vs RNXT Comparison
MIRA vs RNXT Comparison
Compare MIRA & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRA | RNXT |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.0M | 37.0M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MIRA | RNXT |
|---|---|---|
| Price | $1.06 | $0.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 153.2K | ★ 473.6K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | N/A | $2,995.35 |
| Revenue Next Year | N/A | $219.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $0.81 | $0.70 |
| 52 Week High | $2.45 | $1.45 |
Technical Indicators
Market Signals| Indicator | MIRA | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 47.00 | 48.46 |
| Support Level | $0.90 | $0.81 |
| Resistance Level | $1.31 | $1.07 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 55.88 | 32.53 |
Price Performance
Historical ComparisonAbout MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.